New Nasdaq Idea (BIAF) Triggers Our Radar Watch Tuesday (Low Float - 5 Potential Catalysts)

In the fast-changing world of medical diagnostics

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored New Nasdaq Idea (BIAF) Triggers Our Radar Watch Tuesday (Low Float - 5 Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* March 9th Greetings, Friend! In the fast-changing world of medical diagnostics, one emerging company is rewriting the playbook for detecting deadly diseases. By developing new noninvasive testing solutions, it’s setting its sights on transforming early lung cancer detection—making it quicker, more precise, and within reach for millions of people. The market for lung cancer diagnostics, worth nearly $20Bn in 2023, is projected to surge to $38Bn by 2034, creating major opp's for innovative technologies with life‑changing impact. Driven by science and focused on catching lung disease early, this company’s approach could reshape how physicians diagnose and manage respiratory conditions. With fewer than 5Mn shares in its float and a string of noteworthy headlines already in 2026, this Nasdaq-listed idea has firmly earned its spot on our radar: bioAffinity Technologies, Inc. (Nasdaq: BIAF) bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. Early Detection of Lung Cancer Saves Lives Screening is an important tool to find lung cancer at the earliest stages and increase survival. The current protocol for screening people at high risk for lung cancer uses low-dose computed tomography (LDCT) to identify nodules in the lungs. But LDCT has a low positive predictive value that can lead to unnecessary invasive procedures. Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Their first product, CyPath® Lung, is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company, as a Laboratory Developed Test. Growing Platform Technology The Company's commercial noninvasive lung cancer test is the first in a pipeline that includes development of companion diagnostics for asthma and chronic obstructive pulmonary disease (COPD) 92% Sensitivity - 87% Specificity 99% - Negative Predictive Value - 88% Accuracy CyPath® Lung shows high sensitivity and specificity in detecting lung cancer in people with small, indeterminate pulmonary nodules Proprietary AI Analysis of Flow Cytometry Data AI-driven algorithm analyzes complex flow cytometric data from patient sputum samples Profiles the lung microenvironment to differentiate between patients with or without lung cancer Patient-friendly / Physician-focused At-home collection (no needles, no blood) with results 3 days after sample arrives at lab CyPath® Lung - Physician-Focused, Patient-Friendly, Reimbursed by Ins. How the CyPath® Lung Test Works Flow cytometry interrogates the lung microenvironment Sputum samples are processed into a single-cell suspension and labelled before data acquisition with antibodies, reagents, labeling agents and TCPP, a synthetic porphyrin taken up by cancer and cancer-related cells Proprietary AI-driven platform analyzes sample for cancer Automated analysis identifies cell populations of interest and eliminates debris, dead cells, and cell aggregates to distinguish between likely cancer and benign conditions Quality control assures the sample is from the lungs Fluorescent antibody specifically identifies lung macrophages to ensure the sample comes from the lungs AI-driven analysis takes only minutes to identify lung cancer Analysis developed by machine learning detects cell populations indicative of lung cancer A Solid Foundation for Growth Revenue Milestones Achieved in 2025 100% increase in year-over-year revenue and units sold Published multiple case studies and physician testimonials on the human impact of CyPath® Lung Entered major VA medical centers with lung nodule programs Phased field expansion in strategic regional markets in Northeast and Southern U.S. Expanded indications for use of CyPath® Lung for surveillance after treatment and detection of metastatic cancer to the lung Longitudinal Clinical Trial Launches in 2026 Longitudinal study supports inclusion of CyPath® Lung as part of the standard of care for pulmonary nodules Clinical study will evaluate CyPath® Lung performance to support risk stratification, clinical decision-making, detection and survivor surveillance 2000-patient longitudinal clinical trial with up to 20 collection sites including more than a dozen VA and military medical centers are qualified and ready Patient enrollment begins Q1 2026 with financial support from the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), a nonpro-fit organization dedicated to advancing military medicine Find Report Source And More Here: BIAF Website. BIAF Presentation. ----- 5 Potential Catalysts Put (Nasdaq: BIAF) In The Spotlight Tuesday. 1.) BIAF Has An Fairly Low Float (Volatility Potential May Be Explosive). Sporting a float of roughly 4.26Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash for BIAF. 2.) bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients. bioAffinity Technologies’ latest research, presented at the AAAAI 2026 annual meeting, highlights a new diagnostic platform capable of identifying key antibody drug receptors in sputum for therapies like dupilumab and benralizumab. This breakthrough can help physicians tailor asthma and COPD treatments more effectively, improving outcomes while reducing trial-and-error approaches. Using a proprietary flow cytometry platform enhanced with automated AI analysis, the company’s technology aims to guide personalized care, monitor disease progression, and advance precision medicine for millions of respiratory patients globally. 3.) bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test. bioAffinity Technologies announced a validation study with Brooke Army Medical Center to expand CyPath® Lung’s diagnostic capabilities by testing sputum samples obtained via deep suction methods. The study, involving 30–50 patients, aims to demonstrate CyPath® Lung’s reliability in diverse clinical settings and enhance its applicability in early lung cancer detection. This collaboration underscores bioAffinity’s commitment to working with medical professionals and leveraging AI-driven technology to improve early diagnosis, save lives, and strengthen adoption of its innovative noninvasive test. 4.) New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer. A new bioAffinity Technologies case study showcased how its CyPath® Lung test helped avoid an invasive biopsy for a 79-year-old patient with a suspicious lung nodule. The test’s negative result enabled a safe, conservative surveillance plan, later validated by follow-up scans showing no malignancy. With 92% sensitivity, 87% specificity, and 88% accuracy for small nodules, CyPath® Lung continues to prove its clinical value. 5.) bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board. bioAffinity Technologies has expanded its Medical and Scientific Advisory Board by appointing three prominent pulmonary and lung cancer specialists: Drs. David Ost, Daniel Sterman, and J. Scott Ferguson. Their expertise will guide the integration of the company’s CyPath® Lung diagnostic test into clinical practice for early lung cancer detection. These appointments highlight bioAffinity’s dedication to clinical excellence and strategic growth. The strengthened board will help advance innovation, enhance adoption of noninvasive diagnostics, and support the company’s mission to improve patient outcomes through early detection. ----- Coverage is underway on bioAffinity Technologies, Inc. (Nasdaq: BIAF). Be on the lookout for updates coming shortly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/09/2026 and ending on 03/10/2026 to publicly disseminate information about (BIAF:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (BIAF:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/biaf-2xr7h/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice